Title: Retatrutide Weight Loss: Trial 28%, Buyers Online 7.2%
Author: Arthur Harmash
Published: 2026-09-30
Source: https://lymyvoyage.com/articles/retatrutide-weight-loss-trial-buyers
Citations:
- https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
- https://www.safemedicines.org/2026/08/august-24-2026.html
- https://pubmed.ncbi.nlm.nih.gov/37366315/
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://www.fda.gov/news-events/press-announcements/fda-roundup-december-17-2024
- https://vialprices.com/compound/retatrutide.html
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
- https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss
---
Retatrutide is not approved anywhere in the world. It is also being sold by the vial, at about seven dollars a milligram, to people who found it through a search for its price.[^7]
The number that brought them there is 30 percent. Eli Lilly reported in May 2026 that its Phase 3 obesity trial had delivered weight loss on that scale.[^1] A preprint posted three months later followed people taking the same molecule bought outside a trial, and reported 7.2 percent at one year.[^2]
Retatrutide produced up to 30 percent weight loss in a trial. Vials sell online at about seven dollars a milligram. What did the people buying it lose?
The trial figure is doing work in a market the trial has nothing to do with. Retatrutide is approved in no country, so every vial being sold is sold on the strength of someone else's clinical result.
Read the trial number precisely. At 80 weeks the 12 mg dose averaged 28.3 percent. The 30.3 percent figure is from participants who started at a body mass index of 35 or above and continued to 104 weeks.
A preprint followed 378 people taking retatrutide obtained outside a trial. They lost 4.7 percent at three months, 5.3 percent at six and 7.2 percent at one year, against 5.7, 11.9 and 15.5 percent for trial participants.
Most of them did not buy it from a laboratory supplier. About 57 percent got it from online or telehealth vendors and 29 percent from compounding pharmacies.
What complicates the comparison is the evidence for it. The preprint has not been peer reviewed, and it was produced by a data analytics company rather than an academic group. The weaker figure rests on weaker evidence than the trial figure does.
What it cannot show is why. Nobody verified what was in any vial, so a smaller result may mean underdosing, a different substance, or inconsistent use. Weaker results and a weaker product are not the same finding.
The trial result is real and so is the gap. A molecule with no approval anywhere has no lawful price, and the one being quoted per milligram is buying an unverified substance and someone else's trial number.
## What the trial reported, dose by dose
Lilly announced the result of TRIUMPH-1 on 21 May 2026. The trial randomised 2,339 participants to retatrutide at 4 mg, 9 mg or 12 mg, or to placebo.[^1]
| Dose | Average weight loss at 80 weeks | Discontinued for adverse events |
|---|---|---|
| 4 mg | 47.2 lbs, 19.0% | 4.1% |
| 9 mg | 64.4 lbs, 25.9% | 6.9% |
| 12 mg | 70.3 lbs, 28.3% | 11.3% |
| Placebo | — | 4.9% |
Figures as reported by the company in its own release.[^1] Nausea was reported by 28.6, 38.4 and 42.4 percent of the three dose groups against 14.8 percent on placebo.
The 30 percent figure that travels needs its conditions attached. Participants who continued on 12 mg to 104 weeks lost an average of 85.0 lbs, or 30.3 percent, and that group is defined by a starting body mass index of 35 or above.[^1] At 80 weeks, 45.3 percent of the 12 mg group had reached 30 percent or more.
The peer-reviewed evidence is a stage earlier. The Phase 2 trial, published in the New England Journal of Medicine in 2023, randomised 338 adults and reported average weight loss of 24.2 percent at 48 weeks on 12 mg, against 2.1 percent on placebo.[^3]
## Even the trial's own headline depends on which figure you quote
Two accounts of the same trial do not give the same numbers, and the gap is worth naming rather than smoothing.
The company's release and a trade report both put 80-week weight loss at 19.0 percent on 4 mg, 25.9 on 9 mg and 28.3 on 12 mg.[^1][^10] The Pharmaceutical Journal, reporting the day after, gives 17.6 percent, 23.7 and 25.0, with 3.9 percent on placebo.[^11]
Neither source explains the difference, and this article did not find an explanation in either. The likely reason is that the figures come from different analysis populations, one counting everyone randomised and the other counting those who stayed on treatment. That is a guess about a method, not a sourced fact, and it is stated as such here.
What it means practically is that the lower pair is the more conservative reading of the same trial. The article's comparisons below use the company's figures, because they are the ones circulating in the market being examined.
The 104-week extension figure has the same character. It covers 532 participants who began with a body mass index of 35 or above, tolerated their assigned dose, and were then escalated to the maximum tolerated dose for a further 24 weeks.[^11][^10]
## What the people buying it outside a trial got
On 24 August 2026 the Partnership for Safe Medicines reported a study of people taking purported retatrutide obtained outside any trial.[^2] The study is a preprint, manuscript 202608.1193 on Preprints.org, produced by the data analytics company Nference.
It followed 378 people. Reported weight loss was 4.7 percent at three months, 5.3 percent at six months and 7.2 percent at one year. The comparison figures for trial participants over the same intervals were 5.7, 11.9 and 15.5 percent.[^2]
A preprint reports that people taking retatrutide bought outside a trial lost 7.2 percent of body weight at one year, against 15.5 percent for trial participants over the same interval.[^2]
The supply routes matter as much as the outcome. About 57 percent obtained it from online or telehealth vendors, 29 percent from compounding pharmacies and 9 percent from wellness, weight-loss or other clinics.[^2] That is not a research-laboratory market. It is a consumer one.
Three limits on that study, and they are substantial. It has not been peer reviewed. It was produced by a company whose business is health data analytics rather than by an academic group. And it cannot establish what was in any vial, so a smaller result may reflect underdosing, a different substance, inconsistent use, or all three.
This article also could not read the preprint itself. Both the manuscript page and the trade coverage carrying its cardiovascular findings were inaccessible, so the figures above are as reported by the Partnership for Safe Medicines, and the heart-rate numbers reported elsewhere in that coverage are not quoted here.
## The heart-rate question, from sources that can be checked
The published record does say something about heart rate, and it is worth separating from the unreadable coverage.
The Phase 2 trial reported "dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter".[^3] That is the manufacturer's own trial, published in a peer-reviewed journal, describing a real effect that resolved rather than persisted.
For comparison, the label of an approved drug in the same class states the size of the effect plainly. Zepbound, Lilly's tirzepatide product, records that treatment "resulted in a mean increase in heart rate of 1 to 3 beats per minute".[^4]
That is the difference a label makes. An approved product publishes the magnitude of its cardiovascular effect in a document a prescriber must read. An unapproved one has no such document, so a buyer comparing vial prices has nothing to compare on this point at all.
## What "retatrutide cost" is a price for
A price comparison site read the market on 26 August 2026 and put the cheapest supplier at 6.67 dollars per milligram for a 30 mg vial.[^7] The same site carries the standard disclaimer: the products are sold "for laboratory research use only", and "nothing here is intended for human or veterinary use".
The US Food and Drug Administration (FDA), which would have to approve the molecule, has been explicit about what those disclaimers are doing. Its guidance on unapproved weight-loss drugs says companies "illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled 'for research purposes' or 'not for human consumption'".[^5] It adds that these products were distributed to consumers with dosing instructions.
The enforcement record has names and dates. On 17 December 2024 the agency announced warning letters to Xcel Peptides, Swisschems, Summit Research, Prime Peptides and Veronvy over unapproved semaglutide, tirzepatide and retatrutide products.[^6] The letter to Xcel Research, dated 10 December 2024, lists seven peptide products including retatrutide and notes the labels stating "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE".[^8] The agency's finding was that the website's own marketing language established intended human use regardless.
It has not stopped. A warning letter dated 31 March 2026 to Gram Peptides of Rancho Santa Fe, California, names retatrutide and tirzepatide among the products offered, again labelled "Research Use Only" and "not intended for human consumption".[^9]
## What the per-milligram price leaves out
**Nobody has checked the vial.** The agency says unapproved versions "do not undergo FDA's review for safety, effectiveness and quality before they are marketed", and that illegally marketed drugs "may be counterfeit" and "could contain the wrong ingredients or harmful ingredients".[^5]
**The compounded route is not the regulated route either.** The agency states plainly that "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality".[^5] Twenty-nine percent of the preprint's cohort used that route.[^2]
**There is an adverse-event record for the neighbouring molecules.** As of 31 May 2026 the agency had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, including cases it links to dosing errors requiring hospitalisation.[^5]
**The dose schedule in the trial is not a vial.** TRIUMPH-1 titrated participants upward in steps every four weeks under supervision, and 11.3 percent of the 12 mg group still stopped for adverse events.[^1] A vial and a syringe do not carry that schedule.
**And the lawful comparator's price could not be verified here.** Lilly's self-pay pricing pages for Zepbound did not return content for this article, so no dollar figure for the approved alternative is quoted. What can be stated is that the approved product has a label, a dose schedule and a manufacturer answerable for the contents.[^4]
## How to use these numbers
Separate the two numbers before comparing anything. The 30.3 percent belongs to a subgroup of a trial that ran for two years with supervised titration. The 7.2 percent is what a preprint measured in people buying the molecule themselves.
Treat "research use only" as a legal position rather than a description. The agency's own reading is that marketing copy describing appetite suppression and weight loss establishes intended human use, whatever the vial says.[^8][^9]
If the appeal is the molecule rather than the price, the honest answer is to wait or to enrol. Retatrutide has no approval in any country, and the company has not published an approved indication because there is not one.
If the appeal is the price, compare it against an approved product's total, not against the trial's result. The approved options in this class carry a label that states their dose schedule and the size of their cardiovascular effect.[^4]
And if you are already taking something bought this way, tell a clinician what it is and how much. The adverse events in this market are real and are being recorded: 990 reports on one compounded molecule alone.[^5]
[^1]: https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html — Eli Lilly and Company, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial", press release via PR Newswire (published May 21, 2026). Accessed Sep 30, 2026.
[^2]: https://www.safemedicines.org/2026/08/august-24-2026.html — Partnership for Safe Medicines, news digest for Aug 24, 2026, reporting a preprint by Nference posted on Preprints.org as manuscript 202608.1193. Accessed Sep 30, 2026.
[^3]: https://pubmed.ncbi.nlm.nih.gov/37366315/ — Jastreboff AM, Kaplan LM, Frías JP, et al., "Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial", New England Journal of Medicine 2023;389(6):514-526, abstract record via PubMed. Accessed Sep 30, 2026.
[^4]: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b — US National Library of Medicine, DailyMed, "ZEPBOUND (tirzepatide) injection, solution", Eli Lilly and Company, label revised Aug 28, 2026. Accessed Sep 30, 2026.
[^5]: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss — US Food and Drug Administration, "FDA's concerns with unapproved GLP-1 drugs used for weight loss" (last updated Sep 1, 2026). Accessed Sep 30, 2026.
[^6]: https://www.fda.gov/news-events/press-announcements/fda-roundup-december-17-2024 — US Food and Drug Administration, "FDA Roundup: December 17, 2024". Accessed Sep 30, 2026.
[^7]: https://vialprices.com/compound/retatrutide.html — Vial Prices, "Retatrutide price comparison: cheapest per milligram", prices read Aug 26, 2026. Accessed Sep 30, 2026.
[^8]: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024 — US Food and Drug Administration, warning letter to Xcel Research LLC, Sheridan, Wyoming, reference 694608 (dated Dec 10, 2024). Accessed Sep 30, 2026.
[^9]: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026 — US Food and Drug Administration, warning letter to Bernard Gramlich, Gram Peptides, Rancho Santa Fe, California, reference 721806 (dated Mar 31, 2026). Accessed Sep 30, 2026.
[^10]: https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial — AJMC, Giuliana Grossi, "Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1 trial" (published May 21, 2026). Accessed Sep 30, 2026.
[^11]: https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss — The Pharmaceutical Journal, Joanna Robertson, "Phase III retatrutide study demonstrates 30% weight loss" (published May 22, 2026). Accessed Sep 30, 2026.